HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
äŒæ¥ã³ãŒãHSCSW
äŒç€ŸåHeartSciences Inc
äžå Žæ¥Jun 15, 2022
æé«çµå¶è²¬ä»»è
ãCEOãMr. Andrew Simpson
åŸæ¥å¡æ°- -
蚌åžçš®é¡Company Warrant
æ±ºç®ææ«- -
æ¬ç€Ÿæåšå°550 Reserve St, Suite 360
éœåžSOUTHLAKE
蚌åžååŒæNASDAQ Capital Market Consolidated
åœUnited States of America
éµäŸ¿çªå·76092
é»è©±çªå·16822377781
ãŠã§ããµã€ãhttps://heartsciences.com/
äŒæ¥ã³ãŒãHSCSW
äžå Žæ¥Jun 15, 2022
æé«çµå¶è²¬ä»»è
ãCEOãMr. Andrew Simpson
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã